Literature DB >> 28468916

Tumor-Derived α-Fetoprotein Directly Drives Human Natural Killer-Cell Activation and Subsequent Cell Death.

Lazar Vujanovic1,2, Elizabeth C Stahl1, Angela D Pardee1,2, David A Geller3, Allan Tsung3, Simon C Watkins4, Gregory A Gibson4, Walter J Storkus1,5,6, Lisa H Butterfield7,2,3,6.   

Abstract

Hepatocellular carcinoma (HCC) patients with reduced natural killer (NK)-cell numbers and function have been shown to have a poor disease outcome. Mechanisms underlying NK-cell deficiency and dysfunction in HCC patients remain largely unresolved. α-Fetoprotein (AFP) is an oncofetal antigen produced by HCC. Previous studies demonstrated that tumor-derived AFP (tAFP) can indirectly impair NK-cell activity by suppressing dendritic cell function. However, a direct tAFP effect on NK cells remains unexplored. The purpose of this study was to examine the ability of cord blood-derived AFP (nAFP) and that of tAFP to directly modulate human NK-cell activity and longevity in vitro Short-term exposure to tAFP and, especially, nAFP proteins induced a unique proinflammatory, IL2-hyperresponsive phenotype in NK cells as measured by IL1β, IL6, and TNF secretion, CD69 upregulation, and enhanced tumor cell killing. In contrast, extended coculture with tAFP, but not nAFP, negatively affected long-term NK-cell viability. NK-cell activation was directly mediated by the AFP protein itself, whereas their viability was affected by hydrophilic components within the low molecular mass cargo that copurified with tAFP. Identification of the distinct impact of circulating tAFP on NK-cell function and viability may be crucial to developing a strategy to ameliorate HCC patient NK-cell functional deficits. Cancer Immunol Res; 5(6); 493-502. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28468916     DOI: 10.1158/2326-6066.CIR-16-0216

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  8 in total

1.  Hepatocellular cancer-derived alpha fetoprotein uptake reduces CD1 molecules on monocyte-derived dendritic cells.

Authors:  Chunlei Li; Baobao Song; Patricia M Santos; Lisa H Butterfield
Journal:  Cell Immunol       Date:  2018-11-01       Impact factor: 4.868

Review 2.  Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma.

Authors:  Yue Chen; Haoyue Hu; Xianglei Yuan; Xue Fan; Chengda Zhang
Journal:  Front Immunol       Date:  2022-06-10       Impact factor: 8.786

3.  Non-secretion of AFP and neutrophil lymphocyte ratio as predictors for survival in hepatocellular carcinoma patients treated with sorafenib: a large UK cohort.

Authors:  Yuk Ting Ma; Pankaj Punia; Mehran Afshar; Peter Fletcher; Antonio D Bardoli
Journal:  Oncotarget       Date:  2018-03-30

Review 4.  The role of natural killer cells in hepatocellular carcinoma development and treatment: A narrative review.

Authors:  Sarun Juengpanich; Liang Shi; Yasaman Iranmanesh; Jiang Chen; Zhenzhe Cheng; Aaron Kah-Jin Khoo; Long Pan; Yifan Wang; Xiujun Cai
Journal:  Transl Oncol       Date:  2019-06-06       Impact factor: 4.243

Review 5.  Modulating the Crosstalk between the Tumor and Its Microenvironment Using RNA Interference: A Treatment Strategy for Hepatocellular Carcinoma.

Authors:  Mariam Mroweh; Thomas Decaens; Patrice N Marche; Zuzana Macek Jilkova; Flora Clément
Journal:  Int J Mol Sci       Date:  2020-07-24       Impact factor: 5.923

Review 6.  Innate immune cells and their interaction with T cells in hepatocellular carcinoma.

Authors:  Guo-Qing Hong; Dong Cai; Jian-Ping Gong; Xing Lai
Journal:  Oncol Lett       Date:  2020-11-19       Impact factor: 2.967

Review 7.  From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma.

Authors:  Yaojie Fu; Shanshan Liu; Shan Zeng; Hong Shen
Journal:  J Exp Clin Cancer Res       Date:  2019-09-09

8.  Integrative genomic expression analysis reveals stable differences between lung cancer and systemic sclerosis.

Authors:  Heng Li; Liping Ding; Xiaoping Hong; Yulan Chen; Rui Liao; Tingting Wang; Shuhui Meng; Zhenyou Jiang; Dongzhou Liu
Journal:  BMC Cancer       Date:  2021-03-10       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.